Quick Answer
Greenwich LifeSciences, Inc. reported Stockholders Equity of $2.53 million for the year ending 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -62.2% in Stockholders Equity from 2023 to 2024.
- This data is from Greenwich LifeSciences, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$10.27 million | Q2 2019: -$12.87 million | Q3 2019: -$1.21 million | Q1 2020: -$1.42 million | Q2 2020: -$1.46 million | Q3 2020: $4.66 million | Q1 2021: $29.75 million | Q2 2021: $29.16 million | Q3 2021: $28.46 million | Q1 2022: $19.51 million | Q2 2022: $16.97 million | Q3 2022: $15.41 million | Q1 2023: $11.68 million | Q2 2023: $10.65 million | Q3 2023: $8.85 million | Q4 2023: $6.70 million | Q1 2024: $5.12 million | Q2 2024: $5.88 million | Q3 2024: $4.98 million | Q4 2024: $2.53 million | Q1 2025: $1.31 million | Q2 2025: $1.44 million | Q3 2025: $2.18 million.
- Over the full 7 years of available data (2018 to 2024), Greenwich LifeSciences, Inc.'s Stockholders Equity has grown by 125.0%.
- Historical annual values: Fiscal year 2024: $2.53 million | Fiscal year 2023: $6.70 million | Fiscal year 2022: $13.21 million | Fiscal year 2021: $26.83 million | Fiscal year 2020: $27.63 million | Fiscal year 2019: -$1.35 million | Fiscal year 2018: -$10.12 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: